March 27 2023
February 15 2023
February 14 2023
January 30 2023
December 19 2022
October 17 2022
October 06 2022
October 05 2022
Discover the members of Cohort V of the Executive Institute
September 29 2022
Creating a stronger and more sustainable life sciences ecosystem in Canada.
September 26 2022
Op-ed published in La Presse coauthered by Gordon C. McCauley, President & CEO of adMare BioInnovations, and his colleague Lesia Babiak, Head of Canada Government Affairs & Policy at Johnson & Johnson
September 20 2022
adMare BioInnovations welcomes Patricia Gauthier, President and General Manager of Moderna Canada, as the newest member of its Board of Directors. Patricia brings to adMare a wealth of leadership experience in global pharma and biotech.
September 19 2022
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that its positive proof-of-concept data has enabled the Company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.
September 15 2022
Inversago Pharma Inc., a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.
September 08 2022
The Canadian Alliance for Skills and Training in Life Sciences (CASTL) has launched their first series of hands-on training short courses to be delivered at the new CASTL Biomanufacturing Training Facility located in Charlottetown, Prince Edward Island.
June 07 2022
Find Therapeutics Inc. (Montreal, Quebec) and SATT Conectus (Strasbourg, France) have signed an exclusive worldwide license to develop a promising therapy for Multiple Sclerosis (MS) and Optic Neuritis (ON) based on a new class of compounds.
June 07 2022
FORUS Therapeutics Inc ("FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
June 01 2022
adMare is pleased to announce the appointment of Anie Perrault, LL.L, ASC as Vice President, Public Affairs and Communications.
May 18 2022
Toronto May 18, 2022 – adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong…
May 10 2022
Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in…
May 02 2022
Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…
April 22 2022
adMare BioInnovations and BIOQuébec cordially invite you to join your fellow Quebec life sciences leaders for a very special evening to celebrate the official opening of adMare’s new facility. Special guests will…
April 12 2022
adMare Quarterly It has been a busy few months at adMare! From a transformative investment of $92M recently announced by the Minister of Innovation, Science and Industry at our Innovation…
April 08 2022
Labour shortages are hitting virtually every Canadian sector, from coffee shops to car manufacturing – and life sciences is no exception. But what is exceptional about our industry is its…
April 05 2022
MONTREAL, QUEBEC, April 5, 2022 – Molecular Forecaster Inc. (MFI) is excited to announce a partnership with adMare BioInnovations (adMare) to deliver computer-aided drug design (CADD) resources to selected R&D…
March 30 2022
GOVERNMENT OF CANADA RELEASE Government of Canada advances domestic life sciences sector by supporting Canadian companies, talent, and research and development March 30, 2022 – Vancouver, British Columbia –…
March 16 2022
adMare’s President & CEO, Gordon C. McCauley speaks with Dr. Naveed Aziz on the first episode of CGEn’s new podcast, Synapsis, about the health sciences sector and what can be…
March 11 2022
Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health issued a statement on additional measures in response to Vladimir Putin’s…
March 08 2022
The Amplitude Fellowship – Training the next generation of life science entrepreneurs Are you an outstanding life science focused PhD candidate, post doc, MD, or inventor? Do you want to…
March 08 2022
adMare Global Leaders Webinar From Lab bench to clinic: How to solve global health challenges by developing new therapies through innovation and founding new companies Featuring Dr. Robert Langer adMare’s…
February 14 2022
MONTREAL, Feb. 14, 2022 – Find Therapeutics Inc. (‘Find’) is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer. Dr. Douville brings to Find 25…
February 08 2022
Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that…
January 17 2022
MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses…
January 13 2022
MONTREAL, Jan. 11, 2022 – New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives. The enzyme, Glycerol-3-Phosphate…
January 12 2022
Montréal – Québec – January 12th, 2022 –CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative…
December 21 2021
In this issue of adMare Quarterly, we are pleased to share our latest news on building companies, building ecosystems, and building talent to build the Canadian life sciences industry from sea to sea – along with Season’s Greetings and a look back on some 2021 highlights from adMare.
December 16 2021
Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Toronto, Ontario, Canada [December…
December 15 2021
Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better drugs? Join us for adMare’s Industry Builder Webinar Series, featuring Dr. Michel Bouvier. Dr. Bouvier…
November 18 2021
Vancouver, BC and Montreal, QC (November 18, 2021) – adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of…
November 15 2021
Vancouver, BC, and Ottawa, ON (November 15, 2021) – adMare BioInnovations is pleased to announce a collaboration with the University of Ottawa to bring new resources and focus to the…
November 09 2021
Vancouver, BC and Charlottetown, PEI (November 9, 2021) – adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership…
November 02 2021
MONTREAL, Quebec – November 2, 2021: District 3 Innovation Hub, an early-stage startup incubator located at Concordia University, and adMare BioInnovations, a Canadian life sciences leader that builds the industry…
October 21 2021
Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex…
September 28 2021
The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…
September 17 2021
MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL)…
September 13 2021
LAVAL, Quebec–(BUSINESS WIRE)–Sep. 13, 2021– BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related…